Giancarlo Castaman, Silvia Linari, Lisa Pieri, Christian Carulli, Paolo Prosperi, Paolo Tonelli, Francesco Demartis, Rajmonda Fjerza, Monica Attanasio, Mirella Coppo, Francesca Salvianti
Emicizumab is a humanized recombinant bispecific antibody, bridging together activated factor IX (FIXa) and factor X (FX), thus mimicking the activity of FVIII in vivo. Emicizumab is designed for long-term prophylaxis in patients with severe hemophilia A with and without inhibitors. This approach provides constant protection, with significant reduction in bleeding rate and improved quality of life. However, protection provided by emicizumab is not absolute, and clotting factor concentrates (FVIII, rFVIIa, aPCC) may be necessary for post-traumatic bleeding or surgery, with a potential thrombotic risk or difficulty in preventing bleeding...
March 16, 2023: Journal of Clinical Medicine